This, the second of two volumes on personalized medicine in lung cancer, touches upon the recent progress in targeted drug development based on genomics; emerging biomarkers and therapeutic targets such as EMT, cancer stem cells, and the tumor microenvironment; current personalized clinical management and radiation therapy for lung cancers; and the promise of epigenetics and next-generation sequencing for the advancements towards personalized therapy of lung cancer patients. With chapters on state-of-the-art therapies and technologies written by leading experts working to develop novel companion diagnosis tools for the personalized treatment of lung cancer patients, this volume brings readers up-to-date by presenting the current knowledge on the efforts to make personalized management of lung cancer patients a reality.

Provides a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans Addresses statistics and epidemiology of lung cancer, along with the incidence of lung cancer in non-smokers Evaluates the state of current therapiesimmune, targeted therapies against EGFR TKIs, KRAS, ALK and the associated challenges, especially resistance mechanisms

Autorentext

Aamir Ahmad, PhD, is a Scientist at the Wayne State University School of Medicine Department of Pathology and the Karmanos Cancer Institute, with over 100 published scientific articles in peer-reviewed journals and many book chapters. He has been a member of leading cancer organizations such as American Association for Cancer Research (AACR, Philadelphia, USA) and International Union against Cancer (UICC, Geneva, Switzerland). In addition to serving as a reviewer for a number of peer-reviewed scientific journals, he is currently a Section Editor for the journal PLoS ONE responsible for policy drafts for the journal and identification and management of special issues. In addition to the current volume, Dr. Ahmad has worked with Springer to edit two more volumes, Breast Cancer Metastasis and Drug Resistance and Lung Cancer and Personalized Medicine: Current Knowledge and Therapies.

Shirish M. Gadgeel is a Professor in the Department of Oncology at Karmanos Cancer Institute/Wayne State University in Detroit. He is also the co-leader of the Molecular Therapeutics Program of Karmanos Cancer Institute and the Leader of the Multidisciplinary Thoracic Oncology team. He is a member of several professional societies, including the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. He currently serves on the Editorial Board of the journals Cancer and Clinical Lung Cancer. Dr. Gadgeel has been and is a Principal Investigator of several trials focused on the treatment of Lung Cancer. He has over 80 peer reviewed publications.

Inhalt
1 Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.-2 Emerging Biomarkers in Personalized Therapy of Lung Cancer.-3 Epithelial mesenchymal transition in aggressive lung cancers.-4 The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.-5 The microenvironment of lung cancer and therapeutic implications.-6 Epigenetics in Personalized Management of Lung Cancers.-7 Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer.-8 Nanomedicine for Treatment of Lung Cancer.-9 Personalized Therapy of Small Cell Lung Cancer.-10 Personalized Radiation Therapy for Lung Cancer.-11 Current Clinical Management in the era of personalized therapy.-11 Personalized Therapy of Non-Small Cell Lung Cancer.